rs142967124
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_014363.6(SACS):c.2983G>T(p.Val995Phe) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00221 in 1,611,978 control chromosomes in the GnomAD database, including 10 homozygotes. In-silico tool predicts a benign outcome for this variant. 16/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Consequence
NM_014363.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00172 AC: 262AN: 152176Hom.: 1 Cov.: 32
GnomAD3 exomes AF: 0.00185 AC: 465AN: 250846Hom.: 4 AF XY: 0.00199 AC XY: 270AN XY: 135588
GnomAD4 exome AF: 0.00227 AC: 3308AN: 1459686Hom.: 9 Cov.: 36 AF XY: 0.00232 AC XY: 1681AN XY: 725738
GnomAD4 genome AF: 0.00172 AC: 262AN: 152292Hom.: 1 Cov.: 32 AF XY: 0.00158 AC XY: 118AN XY: 74466
ClinVar
Submissions by phenotype
not specified Benign:4
- -
Variant summary: SACS c.2983G>T (p.Val995Phe) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.0022 in 1611978 control chromosomes in the gnomAD database, including 10 homozygotes, providing strong evidence for a benign role of the variant. c.2983G>T has been reported in the literature in at least one compound heterozygous individual affected with autosomal recessive Charlevoix-Saguenay spastic ataxia (ARSACS) with second allele classified on VUS-benign spectrum in ClinVar (e.g. Musante_2022), in an individual affected with spastic cerebellar ataxia with a second variant of unknown phase or classification (e.g. Coutelier_2018), in an individual affected with unexplained early-onset ataxia with second variant classified on VUS-benign spectrum in ClinVar, phase unknown (e.g. Synofzik_2013), or reported as a polymorphism in an individual affected with or with suspected ARSACS with no genotype/second variant reported (e.g. Vermeer_2009). These reports do not provide unequivocal conclusions about association of the variant with Charlevoix-Saguenay spastic ataxia. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 29482223, 35328054, 23497566, 19779133). ClinVar contains an entry for this variant (Variation ID: 218707). Based on the evidence outlined above, the variant was classified as likely benign. -
- -
- -
not provided Benign:3
SACS: BP4, BS2 -
- -
This variant is associated with the following publications: (PMID: 29482223, 19779133, 23497566) -
Charlevoix-Saguenay spastic ataxia Benign:3
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. -
- -
- -
Spastic paraplegia Benign:1
- -
Hereditary spastic paraplegia Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at